Y Mabs Therapeutics Inc Stock Ownership - Who owns Y Mabs Therapeutics?

Insider buying vs selling

Have Y Mabs Therapeutics Inc insiders been buying or selling?
Thomas GadCHIEF BUSINESS OFFICER2024-06-1135,000$12.00
Gerard BerDirector2024-06-10722$12.00
Thomas GadCHIEF BUSINESS OFFICER2024-06-1035,000$12.03
Bo KruseEVP CFO SECRY TREAS.2024-05-3131,371$12.07
Bo KruseEVP CFO SECRY TREAS.2024-05-3131,371$2.00
Bo KruseEVP CFO SECRY TREAS.2024-05-3028,629$12.03
Bo KruseEVP CFO SECRY TREAS.2024-05-3028,629$2.00
Thomas GadCHIEF BUSINESS OFFICER2024-05-237,351$13.00
Thomas GadCHIEF BUSINESS OFFICER2024-05-2125,000$12.00
Vignesh RajahSVP CHIEF MEDICAL OFFICER2024-03-051,711$16.53

1 of 4

YMAB insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when YMAB insiders and whales buy or sell their stock.

YMAB Shareholders

What type of owners hold Y Mabs Therapeutics Inc stock?
Johan Wedellwedellsborg11.92%5,229,205$62.75MInsider
Biotech Aps Wg10.39%4,559,233$54.71MInsider
Blackrock Inc6.51%2,857,257$34.29MInstitution
Thomas Gad5.57%2,442,093$29.31MInsider
Paradigm Biocapital Advisors LP5.09%2,233,610$26.80MInstitution
James Healy5.07%2,225,881$26.71MInsider
Sofinnova Investments Inc5.00%2,194,278$26.33MInstitution
Vanguard Group Inc4.72%2,069,517$24.83MInstitution
Polar Capital Holdings PLC4.17%1,831,000$21.97MInstitution
Point72 Asset Management LP3.48%1,527,100$18.33MInstitution

1 of 3

YMAB vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
YMAB52.43%39.04%Net BuyingNet Selling
MNMD44.29%55.71%Net Selling
APLT82.23%7.92%Net SellingNet Selling
THRD73.27%26.73%Net SellingNet Selling
MREO11.98%4.59%Net BuyingNet Buying

Y Mabs Therapeutics Stock Ownership FAQ

Who owns Y Mabs Therapeutics?

Y Mabs Therapeutics (NASDAQ: YMAB) is owned by 52.43% institutional shareholders, 39.04% Y Mabs Therapeutics insiders, and 8.54% retail investors. Johan Wedellwedellsborg is the largest individual Y Mabs Therapeutics shareholder, owning 5.23M shares representing 11.92% of the company. Johan Wedellwedellsborg's Y Mabs Therapeutics shares are currently valued at $63.27M.

If you're new to stock investing, here's how to buy Y Mabs Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.